CY1119007T1 - Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης - Google Patents

Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης

Info

Publication number
CY1119007T1
CY1119007T1 CY20171100660T CY171100660T CY1119007T1 CY 1119007 T1 CY1119007 T1 CY 1119007T1 CY 20171100660 T CY20171100660 T CY 20171100660T CY 171100660 T CY171100660 T CY 171100660T CY 1119007 T1 CY1119007 T1 CY 1119007T1
Authority
CY
Cyprus
Prior art keywords
methods
pulmonary hypertension
compositions
hypertension treatment
formulations
Prior art date
Application number
CY20171100660T
Other languages
English (en)
Inventor
Luiz Belardinelli
Hunter Campbell Gillies
Faquan Liang
John Shryock
Suya Yang
Original Assignee
Gilead Sciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45939010&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1119007(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences, Inc. filed Critical Gilead Sciences, Inc.
Publication of CY1119007T1 publication Critical patent/CY1119007T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Παρέχονται φαρμακοτεχνικές μορφές που περιλαμβάνουν θεραπευτικώς αποτελεσματικές ποσότητες αμπρισεντάνης ή φαρμακευτικώς αποδεκτό άλας εξ αυτής και τανταλαφίλης ή φαρμακευτικώς αποδεκτό άλας εξ αυτής και μέθοδοι αγωγής και/ή πρόληψης της πνευμονικής υπέρτασης μέσω χορήγησης των φαρμακοτεχνικών μορφών.
CY20171100660T 2010-10-15 2017-06-22 Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης CY1119007T1 (el)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US39352910P 2010-10-15 2010-10-15
US201161490454P 2011-05-26 2011-05-26
US201161497475P 2011-06-15 2011-06-15
PCT/US2011/056404 WO2012051559A2 (en) 2010-10-15 2011-10-14 Compositions and methods of treating pulmonary hypertension

Publications (1)

Publication Number Publication Date
CY1119007T1 true CY1119007T1 (el) 2018-01-10

Family

ID=45939010

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20171100660T CY1119007T1 (el) 2010-10-15 2017-06-22 Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης

Country Status (25)

Country Link
US (3) US20120269898A1 (el)
EP (2) EP2637664B1 (el)
JP (2) JP5806320B2 (el)
KR (2) KR20130069855A (el)
CN (1) CN103458690B (el)
AR (1) AR083422A1 (el)
AU (2) AU2011315891B2 (el)
BR (1) BR112013008983A2 (el)
CA (1) CA2814518C (el)
CY (1) CY1119007T1 (el)
DK (1) DK2637664T3 (el)
EA (2) EA026074B1 (el)
ES (1) ES2627944T3 (el)
HR (1) HRP20170848T1 (el)
HU (1) HUE033346T2 (el)
LT (1) LT2637664T (el)
MX (1) MX346730B (el)
NZ (2) NZ707213A (el)
PL (1) PL2637664T3 (el)
PT (1) PT2637664T (el)
RS (1) RS56135B1 (el)
SI (1) SI2637664T1 (el)
TW (1) TWI542580B (el)
WO (1) WO2012051559A2 (el)
ZA (1) ZA201302746B (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101777E (pt) 2006-12-12 2015-09-18 Gilead Sciences Inc Composição para tratar uma hipertensão pulmonar
SI2637664T1 (sl) 2010-10-15 2017-07-31 Gilead Sciences, Inc. Sestavki in postopki zdravljenja pljučne hipertenzije
WO2014003678A1 (en) * 2012-06-28 2014-01-03 Xspray Microparticles Ab Pharmaceutical compositions comprising ambrisentan and solid dispersion particles containing tadalafil
WO2014174529A2 (en) * 2013-04-23 2014-10-30 Hetero Research Foundation Polymorphs of avanafil
WO2015069839A1 (en) * 2013-11-06 2015-05-14 Gilead Sciences, Inc. Combination therapy for treating pulmonary hypertension
CN105581990A (zh) * 2014-08-27 2016-05-18 人福医药集团股份公司 安立生坦片剂及其制备方法
CA2982436C (en) 2015-03-13 2023-09-12 Indiana University Research And Technology Corporation Targeting cgmp-related phosphodiesterases to reduce cyst formation in cystic kidney disease, and related materials and methods
DK3496739T3 (da) * 2016-07-15 2021-05-10 Acceleron Pharma Inc Sammensætninger omfattende actriia-polypeptider til brug i behandlingen af pulmonal hypertension
BR112019008622A2 (pt) * 2016-10-27 2019-07-09 Pulmokine Inc método para tratar uma condição
US20200215065A1 (en) * 2017-07-07 2020-07-09 The Regents Of The University Of Colorado, A Body Corporate Compositions and method for treating pulmonary hypertension
US11464778B2 (en) 2017-12-26 2022-10-11 Liqmeds Worldwide Limited Liquid oral formulations for sildenafil
CN109406688A (zh) * 2018-09-28 2019-03-01 中国食品药品检定研究院 用于检测产品中违禁药品的标准样品
TW202133851A (zh) * 2019-11-29 2021-09-16 瑞士商艾克泰聯製藥有限公司 治療肺動脈高血壓之方法
EP4076398A4 (en) 2019-12-16 2024-01-03 Tenax Therapeutics, Inc. LEVOSIMENDAN TO TREAT PULMONARY HYPERTENSION ACCOMPANIED BY HEART FAILURE BY MEANS OF PRESERVED EJECTION FRACTION (PH-HF-PEF)
KR102606504B1 (ko) * 2020-04-10 2023-11-29 주식회사 대웅테라퓨틱스 니클로사마이드를 포함하는 폐고혈압의 예방 및 치료용 조성물
CN112826944B (zh) * 2021-01-29 2023-08-15 台州职业技术学院 一种安立生坦包合物及其制备方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US4326525A (en) 1980-10-14 1982-04-27 Alza Corporation Osmotic device that improves delivery properties of agent in situ
US5364620A (en) 1983-12-22 1994-11-15 Elan Corporation, Plc Controlled absorption diltiazem formulation for once daily administration
US4902514A (en) 1988-07-21 1990-02-20 Alza Corporation Dosage form for administering nilvadipine for treating cardiovascular symptoms
US5250534A (en) 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
DE4313412A1 (de) 1993-04-23 1994-10-27 Basf Ag 3-(Het)aryl-Carbonsäurederivate, Verfahren und Zwischenprodukte zu ihrer Herstellung
GB9401090D0 (en) 1994-01-21 1994-03-16 Glaxo Lab Sa Chemical compounds
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
CU23063A3 (es) 1997-11-12 2005-07-19 Bayer Ag Imidazotriazinonas 2-fenil sustituidas como inhibidores de fosfodiesterasas
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
WO2006007213A1 (en) 2004-06-23 2006-01-19 Myogen, Inc. Enoximone formulations and their use in the treatment of pde-iii mediated diseases
US20060205733A1 (en) 2004-08-26 2006-09-14 Encysive Pharmaceuticals Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
CN101072564A (zh) * 2004-08-26 2007-11-14 恩希赛弗制药公司 内皮缩血管肽a受体(eta)拮抗剂与磷酸二酯酶5(pde5)抑制剂的联合及其用途
WO2007122466A1 (en) 2006-04-21 2007-11-01 Pfizer Products Inc. Pyridine[3,4-b]pyrazinones
EP2091539A1 (en) * 2006-12-12 2009-08-26 Gilead Colorado, Inc. Ambrisentan combined with a renin inhibitor for hypertensive disorder
PT2101777E (pt) 2006-12-12 2015-09-18 Gilead Sciences Inc Composição para tratar uma hipertensão pulmonar
US8217155B2 (en) 2007-07-31 2012-07-10 Gilead Colorado, Inc. Metabolites and derivatives of ambrisentan
WO2010062640A1 (en) 2008-10-28 2010-06-03 Gilead Colorado, Inc. Methods for treating idiopathic pulmonary fibrosis and associated complications
SI2637664T1 (sl) 2010-10-15 2017-07-31 Gilead Sciences, Inc. Sestavki in postopki zdravljenja pljučne hipertenzije

Also Published As

Publication number Publication date
CA2814518C (en) 2016-09-20
LT2637664T (lt) 2017-11-10
DK2637664T3 (en) 2017-06-19
EA201691759A1 (ru) 2017-05-31
NZ707213A (en) 2016-12-23
EA201390428A1 (ru) 2014-02-28
MX346730B (es) 2017-03-30
KR20150002876A (ko) 2015-01-07
WO2012051559A2 (en) 2012-04-19
JP5806320B2 (ja) 2015-11-10
NZ610012A (en) 2015-05-29
HRP20170848T1 (hr) 2017-08-25
KR20130069855A (ko) 2013-06-26
AU2016204638A1 (en) 2016-08-04
EA026074B1 (ru) 2017-02-28
SI2637664T1 (sl) 2017-07-31
EP2637664A4 (en) 2014-09-10
EP3106163A1 (en) 2016-12-21
ZA201302746B (en) 2014-06-25
HUE033346T2 (en) 2017-11-28
JP2015178528A (ja) 2015-10-08
AR083422A1 (es) 2013-02-21
BR112013008983A2 (pt) 2016-07-05
CN103458690B (zh) 2016-03-16
TW201219372A (en) 2012-05-16
CN103458690A (zh) 2013-12-18
AU2011315891B2 (en) 2015-08-13
CA2814518A1 (en) 2012-04-19
US9549926B2 (en) 2017-01-24
EP2637664A2 (en) 2013-09-18
US20140275098A1 (en) 2014-09-18
PL2637664T3 (pl) 2017-09-29
WO2012051559A3 (en) 2013-10-17
EP2637664B1 (en) 2017-03-29
AU2016204638B2 (en) 2018-06-07
RS56135B1 (sr) 2017-10-31
TWI542580B (zh) 2016-07-21
US20160346280A1 (en) 2016-12-01
MX2013004190A (es) 2013-07-29
ES2627944T3 (es) 2017-08-01
PT2637664T (pt) 2017-06-22
JP2014506870A (ja) 2014-03-20
AU2011315891A1 (en) 2013-05-23
US20120269898A1 (en) 2012-10-25

Similar Documents

Publication Publication Date Title
CY1119007T1 (el) Συνθεσεις και μεθοδοι αγωγης πνευμονικης υπερτασης
CY1121858T1 (el) Παραγωγα αρυλμεθοξυ ισοϊνδολινης και συνθεσεις που περιλαμβανουν αυτες και μεθοδοι χρησης αυτων
CY1123810T1 (el) Τριφθορομεθυλ υποκατεστημενα πυραζολια ως αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1119490T1 (el) Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
PH12016500024A1 (en) Bromodomain inhibitor
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1118695T1 (el) Αναστολεις απομεθυλασων ιστονων
CY1118340T1 (el) Αναστολεις κινασης
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
CY1118947T1 (el) Ασυμμετρες ουριες και ιατρικες χρησεις αυτων
EA201591363A1 (ru) Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn
PE20121617A1 (es) Derivados de oxazina como inhibidores de bace
PH12019501896A1 (en) Therapeutic dendrimers
EA201100971A1 (ru) Производные пиримидининдола для лечения злокачественного новообразования
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201100358A1 (ru) Дабигатран для чрескожной хирургической катетеризации сердца
CY1124907T1 (el) Αναστολεις καλλικρεϊνης στο ανθρωπινο πλασμα
CY1116234T1 (el) Υποκατεστημενα 2-οξυ-κινολινο-3-καρβοξαμιδια σαν διαμορφωτες kcnq2/3
EA201692298A1 (ru) Производные карбоксамидов
CY1114760T1 (el) Θεραπευτικη αγωγη αθηροσκληρωσης
EA201700356A1 (ru) Новые циклопропанбензофуранилпиридопиразиндионы
TW201713630A (en) Substituted quinazoline compounds and methods of use thereof
CY1118255T1 (el) Υποκατεστημενα 6-αμινο-νικοτιναμιδια τα οποια φερουν μια ομαδα που περιεχει οη ως διαμορφωτες των kcnq2/3
TR201900156T4 (tr) Tüberküloz ve ilgili hastalıkların tedavisi için kinolil hidrazonlar.